Colorado

Back to map

Showing 11-20 of 24 grants

Title Institution Researcher Program Duration Total Award Amount
Antigenic Targets of CD4 T cells across the stages of type 1 diabetes Regents of the University of Colorado Maki Nakayama Cures 01-August-2022 to 31-July-2026 $749.998,87
Validation of Enzyme-linked immunosorbent assay (ELISA) to detect insulin autoantibodies Regents of the University of Colorado Liping Yu Cures 01-June-2025 to 31-May-2027 $453.852,00
Innovating Methods for AssessinG INsulin Action in Type ONe diabetes (IMAGINATiON) Regents of the University of Colorado Kristen Nadeau Improving Lives 01-December-2021 to 31-December-2026 $445.816,29
Islet autoantibody concordance and metabolic monitoring of individuals identified at risk for type 1 diabetes through population-based screening Regents of the University of Colorado Kimber Simmons Cures 01-July-2023 to 31-December-2026 $750.000,00
Investigating the association between environmental contaminants and progression to autoimmune disease Regents of the University of Colorado Jill Norris Cures 01-September-2026 to 31-August-2027 $149.999,97
Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes Regents of the University of Colorado Jessica Kendrick Improving Lives 01-October-2022 to 31-October-2027 $899.235,00
EFFICACY AND SAFETY OF ONCE WEEKLY SEMAGLUTIDE IN ADULTS WITH OBESITY AND INADEQUATELY CONTROLLED TYPE 1 DIABETES USING HYBRID CLOSED-LOOP SYSTEM Regents of the University of Colorado Janet Snell-Bergeon Improving Lives 01-November-2022 to 31-October-2027 $2.282.771,83
Cognitive behavioral therapy to address anxiety in pre symptomatic type 1 diabetes Regents of the University of Colorado Holly O’Donnell Cures 01-July-2024 to 30-June-2027 $600.000,00
Engaging Interest Holders to Measure Psychological Impacts and Patient-Reported Outcomes of Treatment with Disease-Modifying Therapy in T1D Regents of the University of Colorado Holly O’Donnell Cures 01-August-2026 to 31-July-2029 $846.023,00
Genetically engineered human pluripotent stem cells enabling programmable β-cell differentiation for type 1 diabetes therapy. Regents of the University of Colorado Han Zhu Cures 01-October-2026 to 30-September-2029 $749.996,48